AMPH Q2 2025 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$174M-4.4% YoY

Gross Profit

$86M49.6% margin

Operating Income

$42M24.2% margin

Net Income

$31M17.8% margin

EPS (Diluted)

$0.64

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$25M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$858M

Stockholders' Equity

$757M

Cash & Equivalents

$188M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$174M	$182M	-4.4%
Gross Profit	$86M	$95M	-9.1%
Operating Income	$42M	$55M	-23.6%
Net Income	$31M	$38M	-18.2%

Revenue Segments

Total product revenues, net

$174M50%

Other Products

$53M15%

BAQSIMI

$47M13%

Primatene MIST

$23M7%

Glucagon

$21M6%

Epinephrine

$16M5%

Lidocaine

$15M4%

Geographic Segments

UNITED STATES

$167M96%

FRANCE

$7M4%

CHINA

$299,0000%